| Literature DB >> 33669698 |
Przemysław Kołodziej1, Marcin Nicoś2, Paweł A Krawczyk2, Jacek Bogucki3, Agnieszka Karczmarczyk4, Daniel Zalewski1, Tomasz Kubrak5, Elżbieta Kołodziej6, Anna Makuch-Kocka7, Barbara Madej-Czerwonka8,9, Bartosz J Płachno10, Janusz Kocki6, Anna Bogucka-Kocka1.
Abstract
There is an urgent need to seek new molecular biomarkers helpful in diagnosing and treating breast cancer. In this elaboration, we performed a molecular analysis of mutations and expression of genes within the PI3K/Akt/mTOR pathway in patients with ductal breast cancer of various malignancy levels. We recognized significant correlations between the expression levels of the studied genes. We also performed a bioinformatics analysis of the data available on the international database TCGA and compared them with our own research. Studies on mutations and expression of genes were conducted using High-Resolution Melt PCR (HRM-PCR), Allele-Specific-quantitative PCR (ASP-qPCR), Real-Time PCR molecular methods in a group of women with ductal breast cancer. Bioinformatics analysis was carried out using web source Ualcan and bc-GenExMiner. In the studied group of women, it was observed that the prevalence of mutations in the studied PIK3CA and AKT1 genes was 29.63%. It was stated that the average expression level of the PIK3CA, PIK3R1, PTEN genes in the group of breast cancer patients is lower in comparison to the control group, while the average expression level of the AKT1 and mTOR genes in the studied group was higher in comparison to the control group. It was also indicated that in the group of patients with mutations in the area of the PIK3CA and AKT1 genes, the PIK3CA gene expression level is statistically significantly lower than in the group without mutations. According to our knowledge, we demonstrate, for the first time, that there is a very strong positive correlation between the levels of AKT1 and mTOR gene expression in the case of patients with mutations and without mutations.Entities:
Keywords: PI3K/Akt/mTOR pathway; biomarkers; breast cancer; expressions of genes; mutations; therapeutic targets
Mesh:
Substances:
Year: 2021 PMID: 33669698 PMCID: PMC7922286 DOI: 10.3390/ijms22042061
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923